Hans Ivar Robinson

Hans Ivar Robinson has been involved in the business sector since 1993, when they began their career as a Sales Representative and Regional Sales Manager for Pharmacia. Hans Ivar then moved to AstraZeneca in 1995, where they held the role of Regional Business Director, Europe and VP Sales & Marketing. In 2006, they joined Pronova Biopharma as Vice President Pharmaceuticals and Head of Business Development. In 2010, they founded Birk Venture AS and served as CEO. In 2011, they became a Non Executive Board Member for APIM Therapeutics AS, BerGenBio AS, and Nextera AS. In 2012, they were appointed Non-Executive Director for Targovax and Chairman and Co-Founder for Nextera AS. In 2016, they became Chairman and Co-Founder of Zelluna Immunotherapy and in 2021, they were appointed Non Executive Board Member for Accession Therapeutics Limited.

Hans Ivar Robinson attended the Norwegian School of Economics (NHH) from 1987 to 1991, where they earned a Master in Science of Business (Siviløkonom). Hans Ivar then attended the University of Bergen (UiB) in 1991 to earn a Law degree. Finally, in 1999 to 2000, they attended the IMD Program for Executive Development.